The Increased Risk of Diabetes and Diabetes-Related Eye Disease in Black Americans

Eye Disease in Black Americans: Black History Month is a time to honor the triumphs and struggles of Black Americans throughout history.

It’s also a time to look to the future and activate change. There is much to improve when it comes to the health and wellbeing of Black Americans who are historically at increased risk for many illnesses, including diabetes and diabetes-related eye disease.

Kristen Nwanyanwu, MD, MBA, MHS, a practicing ophthalmologist and vitreoretinal surgeon at Yale School of Medicine, represents one of the many Black American professionals committed to improving the health of her patients. In addition to her clinical work, she serves as the principal investigator for the National Institutes of Health (NIH)-funded Sight-Saving Engagement and Evaluation in New Haven (SEEN) Program, a multi-method approach to identifying and addressing health disparities in diabetic retinopathy.

Diabetic retinopathy is an eye condition that occurs when high blood glucose (blood sugar) levels damage the blood vessels of the retina.[i] Symptoms can include blurred or distorted vision, impaired colors, floating spots, or streaks in one’s vision, and blindness.[ii] Black Americans are at a higher risk for eye disease, including diabetic retinopathy, cataracts, and glaucoma that are likely due to inequities within the health care system.[iii]

“Our country was built on slavery and as a result, our health care system doesn’t adequately serve Black Americans. There is mistrust of the medical community among minorities. We need to work to rebuild that trust,” said Dr. Nwanyanwu. There are more than 825,000 Black Americans in the United States who have diabetic retinopathy.[iv] Tiffani Martin knows the effects all too well.

The Increased Risk Of Diabetes And Diabetes-Related Eye Disease In Black Americans

At five years old, Tiffani was diagnosed with type 1 diabetes. As she got older, specifically during her college years, diabetes management was not a priority in her life and her health and eyesight were negatively impacted. Her health worsened and Tiffani was diagnosed with diabetic retinopathy at just 27 years old. Unfortunately, after eight surgeries on both eyes, she suffered complete vision loss.

Since then, Tiffani has taken great strides to improve her health. Her primary focus has been to advocate for proper diabetes management with healthy lifestyle choices, so no one has to experience the complications she endured. “You don’t die from diabetes, you die from mismanagement,” said Tiffani. One way she has advocated for others is through her participation with Focus on Diabetes™ (FOD), the eye health initiative from the American Diabetes Association® (ADA). FOD was formed by the ADA and Visionary Partners—VSP Vision Care® and Regeneron—to raise awareness of the connection between diabetes and eye health.

Minorities, including Black Americans, have a higher burden of diabetes, worse diabetes control, and are more likely to experience complications[i] due to a combination of risk factors including lack of access to health care and socioeconomic status. However, this does not have to be the case.[ii] Early detection, timely treatment, and appropriate follow-up care can reduce a person’s risk for severe or complete vision loss from diabetes-related eye disease by 95 percent.[iii]

Anyone living with diabetes is at risk for diabetes-related eye diseases, such as diabetic retinopathy. As Tiffani and Dr. Nwanyanwu know, one step you can take to manage your diabetes and eye health is getting an annual eye exam with dilation to allow for a more thorough examination of the eye. An annual eye exam can catch conditions early before permanent damage is done. Some diabetic eye diseases have no signs or symptoms until they are too obvious to ignore, as was the case with Tiffani. But by regularly staying connected with a doctor, you can track any changes to your vision over time and take necessary action before problems get worse.

For some, taking the next step in the eye health journey can be difficult or hard to prioritize. For others, it may be unclear who to go to for help. But it is never too late to get started and take steps toward improving your eye care and overall health. This month, encourage your patients to take Dr. Nwanyanwu and Tiffani’s advice by scheduling an annual eye exam and motivate others in the community to get their eyes checked too.

For more information, visit for resources, podcast episodes, guides, and more, including a free Type 2 Diabetes Risk Test and a diabetic retinopathy risk test.

[i] FDA. (2020, April 10). Fighting Diabetes’ Deadly Impact on Minorities. U.S. Food and Drug Administration. Retrieved from

[ii] FDA. (2020, April 10). Fighting Diabetes’ Deadly Impact on Minorities. U.S. Food and Drug Administration. Retrieved from

[iii] People With Diabetes Can Prevent Vision Loss,” n.d.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy